Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.

scientific article published on 3 September 2014

Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S00277-014-2187-9
P698PubMed publication ID25178517

P50authorDavid D. SmithQ37837060
Raquel IzumiQ114341073
P2093author name stringAhmed Hamdy
Joseph J Buggy
Danelle F James
Fong Clow
Maria Fardis
Mei Cheng
Leanne Goldstein
Lori A Kunkel
P2860cites workGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesQ24616084
A new look at the statistical model identificationQ26778401
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaQ29620690
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaQ30371806
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesQ33893704
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoQ34029869
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemiaQ34249777
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.Q34289493
The B cell antigen receptor controls integrin activity through Btk and PLCgamma2.Q42945085
Regression and time series model selection in small samplesQ56390547
Bruton's Tyrosine Kinase and Phospholipase Cγ2 Mediate Chemokine-Controlled B Cell Migration and HomingQ58324020
P433issue2
P921main subjectlymphocyteQ715347
chronic lymphocytic leukemiaQ1088156
P304page(s)249-256
P577publication date2014-09-03
P1433published inAnnals of HematologyQ15766509
P1476titleModeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib
P478volume94

Reverse relations

cites work (P2860)
Q38542260Ibrutinib for the treatment of Waldenström macroglobulinemia
Q91930615Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
Q38550810Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment
Q35558057Novel and emerging targeted-based cancer therapy agents and methods
Q35450520Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

Search more.